Sanofi and Teva report duvakitug maintenance-study data at UEG Week
Sanofi and Teva have reported maintenance-study findings for duvakitug, an investigational antibody targeting TL1A in inflammatory bowel disease.

Edivro Company News · Original attributed summary. Source announcement: 2026-10-20.
Sanofi and Teva have reported maintenance-study findings for duvakitug, an investigational antibody targeting TL1A in inflammatory bowel disease. Their 20 October update covers a phase 2b long-term extension presented at UEG Week in Barcelona.
The extension included 130 patients with ulcerative colitis or Crohn’s disease who had responded to the earlier induction study. They received one of two duvakitug doses every four weeks. The sponsors report maintained improvements across several measures through week 44 of maintenance treatment.
Does this mean duvakitug is approved?
The release describes an investigational treatment and sponsor-reported study results. It does not announce regulatory approval. Because the extension enrolled earlier responders, its results should not be treated as outcomes for an unselected population starting treatment. The distinction matters when assessing durability against the original induction-stage evidence.
Questions about this story
These answers summarise the article and refer to its original reporting period.
Does this mean duvakitug is approved?
The release describes an investigational treatment and sponsor-reported study results. It does not announce regulatory approval. Because the extension enrolled earlier responders, its results should not be treated as outcomes for an unselected population starting treatment. The distinction matters when assessing durability against the original induction-stage evidence.
What did Sanofi and Teva have report?
Sanofi and Teva have reported maintenance-study findings for duvakitug, an investigational antibody targeting TL1A in inflammatory bowel disease. Their 20 October update covers a phase 2b long-term extension presented at UEG Week in Barcelona.
Publisher
Edivro Company News

